Benjamin Ortiz to Humans
This is a "connection" page, showing publications Benjamin Ortiz has written about Humans.
Connection Strength
0.164
-
Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. J Allergy Clin Immunol Pract. 2022 03; 10(3):732-741.
Score: 0.033
-
Kucerov?-Levisohn M, Knirr S, Mejia RI, Ortiz BD. The 3'-Ja Region of the TCRa Locus Bears Gene Regulatory Activity in Thymic and Peripheral T Cells. PLoS One. 2015; 10(7):e0132856.
Score: 0.021
-
Lahiji A, Kucerov?-Levisohn M, Holmes R, Z??iga-Pfl?cker JC, Ortiz BD. Adapting in vitro embryonic stem cell differentiation to the study of locus control regions. J Immunol Methods. 2014 May; 407:135-45.
Score: 0.019
-
Arsov I, Adebayo A, Kucerova-Levisohn M, Haye J, MacNeil M, Papavasiliou FN, Yue Z, Ortiz BD. A role for autophagic protein beclin 1 early in lymphocyte development. J Immunol. 2011 Feb 15; 186(4):2201-9.
Score: 0.016
-
Knirr S, Gomos-Klein J, Andino BE, Harrow F, Erhard KF, Kovalovsky D, Sant'Angelo DB, Ortiz BD. Ectopic T cell receptor-a locus control region activity in B cells is suppressed by direct linkage to two flanking genes at once. PLoS One. 2010 Nov 22; 5(11):e15527.
Score: 0.015
-
Harrow F, Ortiz BD. The TCRalpha locus control region specifies thymic, but not peripheral, patterns of TCRalpha gene expression. J Immunol. 2005 Nov 15; 175(10):6659-67.
Score: 0.011
-
Harrow F, Amuta JU, Hutchinson SR, Akwaa F, Ortiz BD. Factors binding a non-classical Cis-element prevent heterochromatin effects on locus control region activity. J Biol Chem. 2004 Apr 23; 279(17):17842-9.
Score: 0.010
-
Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2023 04; 11(4):1213-1220.e2.
Score: 0.009
-
Rabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, Deniz Y. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype. J Allergy Clin Immunol Pract. 2022 11; 10(11):2916-2924.e4.
Score: 0.009
-
Szefler SJ, Casale TB, Haselkorn T, Yoo B, Ortiz B, Kattan M, Busse WW. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. J Allergy Clin Immunol Pract. 2020 09; 8(8):2673-2680.e3.
Score: 0.007
-
Li P, Kavati A, Puckett JT, Jahnke J, Busse P, Hanania NA, Ortiz B, Doshi JA. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
Score: 0.007
-
Beck-Sague CM, Arrieta A, Pinzon-Iregui MC, Ortiz B, Dean AG, Cuddihy A, Gasana J. Trends in Racial and Ethnic Disparities in Childhood Asthma in Miami, Florida: 2005-2013. J Immigr Minor Health. 2018 Dec; 20(6):1429-1437.
Score: 0.007